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ABSTRACT  
Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), is a highly complex pathogen 
estimated to have caused more deaths than any other infectious agent throughout human existence. 
Despite global efforts to eradicate TB, this is still a leading cause of death by infectious disease, second 
only to the human immunodeficiency virus (HIV). Although public health measures have greatly diminished 
TB burden, the reality is that little has changed in anti-TB therapy and vaccination over the past decades. 
As an obligatory intracellular pathogen Mtb has co-evolved with its human host for over 70 thousand years. 
This timeframe has given Mtb ample opportunity to evolve its virulence mechanisms in order to thrive in 
the harsh conditions imposed by the immune system and eventually allowing its transmission between 
hosts. In light of this ancient history between host and pathogen, a greater understanding of Mtb and its 
interactions with the host will be required to develop more efficient anti-TB drugs and vaccines. In this work 
we have focused on the role of the Mtb protein Rv0101, a non-ribosomal peptide synthetase predicted to 
be involved in lipid metabolism and cell wall biogenesis, during infection. We found that mice infected with 
a Mtb mutant deficient for Rv0101 have a transient lower lung bacterial burden during the early stages of 
infection. Additionally, in mice infected with this strain the dissemination of the bacterium to the spleen 
was delayed and remained lower up to 90 days post-infection. These differences were accompanied by a 
diminished recruitment of activated CD4+ T cells, inflammatory monocytes and an overall lower 
immunopathology. Furthermore, mice with severely compromised or absent adaptive immune response 
were able to survive infection with this mutant strain at least twice as long as animals infected with the 
complemented strain. In summary, we have shown that Rv0101 is a virulence factor required by Mtb to 
optimally overcome the innate immune response of the host, in addition to being a potent inducer of 
immunopathology. Characterizing the role of key Mtb molecules in infection is urgently needed to 
understand how the pathogen overcomes and modulates the host immune response to allow for its 
persistence and transmission. In turn, this knowledge may provide good drug targets and a better rational 
for vaccine design. 
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RESUMO 
O Mycobacterium tuberculosis (Mtb), agente etiológico da tuberculose (TB), é um agente patogénico 
altamente complexo sendo estimado que tenha levado a mais mortes que qualquer outro agente 
infeccioso ao longo da existência humana. Apesar de esforços globais para erradicar a TB, ela continua a 
liderar como uma das causas de morte por doença infecciosa, sendo ultrapassada apenas pelo vírus da 
imunodeficiência humana (HIV). Apesar de medidas de saúde pública terem diminuído o fardo da TB, a 
realidade é que nas ultimas décadas pouco mudou em termos da terapia anti-TB e vacinação. Como um 
patógeno intracelular obrigatório, o Mtb co-evoluiu com o seu hospedeiro humano durante mais de 70 mil 
anos. Esta janela temporal conferiu ao Mtb amplas oportunidades para evoluir os seus mecanismos de 
virulência de forma a prosperar no ambiente hostil imposto pelo sistema imune inato, eventualmente 
permitindo a sua transmissão entre hospedeiros. À luz deste história milenar entre hospedeiro e patógeno, 
uma maior compreensão do Mtb e das suas interacções com o hospedeiro serão necessárias ao 
desenvolvimento de antibióticos e vacinas mais eficientes. Neste trabalho focámo-nos no papel durante a 
infecção do Rv0101 do Mtb, uma sintetase peptídica não ribossomal previsivelmente envolvida em 
metabolismo lipídico e na biogénese da parede celular. Mostramos que ratinhos infectados com um 
mutante deficiente para o Rv0101 apresentam uma carga bacteriana temporariamente inferior durante o 
estágio inicial da infecção. Além disso, esses mesmos ratinhos apresentaram um aparecimento tardio da 
bactéria no baço e controlaram-na melhor pelo menos até ao dia 90 após a infecção. Estas diferenças 
foram acompanhadas por um recrutamento diminuído de células T CD4+, monócitos inflamatórios e em 
geral uma menor imunopatologia. Adicionalmente, ratinhos sem sistema imune adaptativo, ou com o 
mesmo severamente comprometido, infectados com com esta estirpe mutante conseguiram sobreviver 
pelo menos o dobro do tempo que aqueles infectados com a estirpe complementada. Resumidamente, 
mostramos que o Rv0101 é um factor de virulência do Mtb, necessário para uma óptima superação da 
resposta imune inata do hospedeiro, sendo também capaz de induzir diferenças imunopatológicas 
duradouras. A caracterização do papel de moléculas do Mtb durante a infecção será necessário para 
compreender como o patógeno supera e modula a resposta imunitária do hospedeiro, permitindo a sua 
persistência e transmissão. Por sua vez, este conhecimento pode providenciar bons alvos para novas 
drogas e assistir no desenho de novas vacinas. 
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1. Epidemiology 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb). As a 
predominantly lung disease, some of its main clinical features include sputum producing chronic cough, 
appetite and weight loss, night sweats, fever, hemoptysis and ultimately mortal respiratory failure in case 
treatment fails1. To the furthest extent of our knowledge, TB has killed more people than any other 
infectious disease, and it is estimated to have killed more than smallpox, malaria, plague, influenza, 
cholera and acquired immune deficiency syndrome (AIDS) combined in the past two hundred years2. 
Despite major global efforts towards prevention and treatment, TB remains one of the leading causes of 
death due to infectious disease, second only to human immunodeficiency virus (HIV)3. In is estimated that 
2 billion people are affected by a latent form of this disease and in 2013 alone 9 million new cases of 
active TB and 1.5 million deaths were registered3. Although the numbers of new TB cases and its death toll 
are still a matter of grievous concern, they are in drastic contrast to the reality observed during the first half 
of the twentieth century2,3. Since the beginning of the twenty first century, there has been an average 1.5% 
decrease of TB incidence per year, accompanied by an overall decrease of disease prevalence and 
mortality, and a stabilization of TB incidence among HIV-positive patients3. Even though these data are 
overall positive, a drastic decrease in the drop of TB incidence rate was observed between 2012 and 2013, 
registering a drop of 0.6%, less than half of the average since 20002,3. To reach the milestone of less than a 
TB case per million individuals set by the World Health Organization (WHO) for 2050, numerous 
roadblocks will have to be overcome. Among these, the most notorious are the absence of an efficient 
vaccine, the lack of fast and reliable diagnostic tools and the requirement for more efficient anti-
mycobacterial drugs. Furthermore, the large number of TB/HIV co-infections and the increased incidence 
of infections with multidrug resistant (MDR) Mtb strains further prevent the success of this milestone. 
Indeed, the current strategy to stave off TB is based on public health measures, a 50 years old multidrug 
regimen for at least six months and the inconsistent protection of the Bacillus Calmette-Guérin (BCG) 
vaccine3,4. It is clear that a greater understanding regarding the mechanisms underlying the success Mtb as 
a pathogen is required to develop more efficient vaccines and drugs. In the past few decades, efforts have 
been made to close this gap of knowledge, both regarding the immune system, the pathogen and their 
interactions, a topic that will be further developed in this thesis.   
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2. Early events in the immune response to Mtb 
2.1. Transmission 
It is thought that transmission of Mtb occurs when an infected individual with an advanced form of TB, 
characterized by high bacterial burden coughs and disrupted lesions with access to the airways, coughs 
and releases small bacteria-containing droplets into the atmosphere, which will subsequently be inhaled by 
individuals in close proximity5. Although transmission models of TB have not yet been fully established, it is 
though that mainly the smaller infectious droplets, containing fewer bacteria, will make it past the upper 
respiratory track, and into the relatively sterile environment of the distal alveoli6–8.   
2.2. Innate immune response 
2.2.1. Recognition 
Once in the distal alveoli, recognition and phagocytosis of the bacteria occurs mainly by alveolar 
macrophages, but also by dendritic cells (DCs), monocytes, neutrophils and even  by epithelial cells 9–14. 
Several receptors expressed in phagocytic cells are known to bind pathogen-associated molecular patterns 
(PAMPs) present in Mtb. These receptors include toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2), C-type lectin receptors (CLRs), scavenger receptors 
(SRs) and complement receptors (CRs)15,16. Although in vitro studies have revealed a specific role for many 
of these receptors in response to Mtb, most in vivo works using animals deficient for a single receptor 
revealed only a minor or no phenotype16. These studies suggest that recognition of Mtb by innate immune 
cells is a complex event requiring multiple receptors, with some of them probably sharing some degree of 
redundancy16. 
2.2.2. Inflammatory mediators  
Upon recognition and internalization, a vast array of inflammatory mediators is released to the vicinity of 
the infected cell in response to stimulation of pattern-recognition receptors (PRRs) by Mtb PAMPs17,18. These 
mediators include the interleukin (IL)- 12 subunit IL-12p40, tumor necrosis factor α (TNF-α), IL-6 and IL-
1β, eicosanoids, type-I interferons (IFN) and chemokines18. Together these molecules shape the immune 
response to Mtb.   
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2.2.2.1. IL-12p40 - homodimers and heterodimers  
Overall, the relevance of IL-12p40 derived cytokines is highlighted by the fact that humans with mutations 
on the IL-12β1 receptor present higher susceptibility to TB resulting in increased incidence, severity and 
disease dissemination19–25.   
IL-12p40 dimerizes either with another IL-12p40 molecule, IL-12p35 or IL23-p19, forming IL-12p80, IL-12 
(also known as IL-12p70) and IL-23, respectively18,26. IL-12p80 is readily formed after infection and is 
essential to induce a migratory phenotype in DCs, allowing them to travel to the lymph node where naïve T 
cells will be activated5,14,18,27, thus triggering and adaptive immune response. This IL-12p80 dependent 
mechanism is believed to be enhanced through the expression of a splice variant of the IL-12β1 receptor 
(which binds to IL-12p40) by DCs early after infection28. Although IL-12p80 is important in the early events 
leading to the adaptive immune response, it is unable to trigger the production of IFN-γ, a critical cytokine 
required for the control of Mtb29. 
IL-12p40 also dimerizes with IL-12p35. Unlike IL-12p40, IL-12p35 is not significantly expressed in the 
early stages after Mtb infection29. Accordingly, the critical role of IL-12p70 does not involve the initial 
triggering of an adaptive immune response to Mtb, as is the case of IL-12p8019,30. Instead, IL-12p70 is 
essential in the induction and maintenance of IFN-γ-producing cells, which are protective in later stages of 
infection19,30. Thus, IL-12p70 is essential for long lasting protection against Mtb, as mice lacking this 
cytokine are unable to control bacterial proliferation19,29. 
The dimerization of IL-12p40 with IL-23p19 leads to the formation of IL-23 which, in contrast to IL-12p70, 
is not essential to control Mtb infection14. Indeed, mice lacking IL-23p19 infected by a low-dose aerosol are 
equally able to control Mtb as WT mice30. However, IL-23 is required for optimal differentiation of an IL-17-
producing adaptive immune response30. The relevance of this type of adaptive immune response is 
discussed later in this work. Furthermore, IL-23 is known to share some functions with IL-12p70. 
Specifically, IL-12p35 deficient mice are able to generate an IFN-γ-producing adaptive immune response 
through an IL-23p19 dependent mechanism30. However, this mechanism does not fully compensate the 
absence of IL-12p70, as the adaptive immune response triggered is not sufficient to control Mtb30.  
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2.2.2.2. IL-6 
Although IL-6 is rapidly produced by phagocytes after Mtb challenge, its relevance in the context of 
infection is still a matter of debate18. It is currently known that IL-6 is required for the induction of an 
optimal T cell response31, even though after low dose aerosol infection IL-6 deficient mice are able to 
control Mtb with only a slight increase in lung bacterial burden32.  On the other hand, when these mice are 
exposed to a high-dose aerosol they rapidly succumb to infection33, clearly pointing for a role for this 
cytokine as a necessary response factor against high-burden challenges.  
2.2.2.3. TNF-α 
Unlike IL-6, it is well established that TNF-α is essential to control Mtb, as TNF-α deficient mice are unable 
to control the growth of Mtb and quickly succumb to infection34–36. The importance of this cytokine is further 
emphasized by human studies. Indeed, rheumatoid arthritis and inflammatory bowel disease patients 
undergoing the standard anti-TNF therapy have an increased chance to reactivate a latent case of TB37–39. 
TNF-α exerts its main function in controlling Mtb by activating microbicidal mechanisms in macrophages, 
thus allowing for the elimination of Mtb10. In addition to this critical function during the earlier stages of TB, 
TNF-α plays a role in the formation of the granuloma and is essential to maintain its structural integrity 
during infection, allowing a better control of Mtb during the chronic stage of infection40,41. 
2.2.2.4 The IL-1β – Eicosanoid – Type-1 IFN network 
The exact role of IL-1β in TB has not yet been fully characterized, but it is clear that mice lacking this 
cytokine or its receptor are highly susceptible to Mtb, and succumb shortly after infection42,43. Furthermore, 
this cytokine requires a tight regulation, as its overproduction leads to extreme immunopathological 
features associated with poor survival44. Even though IL-1β exerts a protective role against Mtb, it does so 
independently of TNF-α, IFN-γ, nitric oxide synthase 2 (NOS2) and IL-12p4044,45. Indeed, the levels of these 
molecules were not diminished in mice deficient for IL-1β signaling when compared to WT animals44,45. 
More recently however, the role of IL-1β has been partially attributed to the regulation of the eicosanoid 
pathway46.  
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The eicosanoid pathway has only recently been implicated in the immune response to Mtb47,48. The 
eicosanoids are immunomodulatory lipids derived from arachidonic acid and are divided into 3 distinct 
classes: prostaglandins (PGs), leukotrienes (LTs) and lipoxins (LXs)49. All these classes of eicosanoids are 
produced by infected macrophages and it has been proposed that the ratio between each individual class 
may significantly impact the outcome of infection14. Specifically, PGE2 is known to induce apoptosis of 
infected cells leading to phagocytosis of apoptotic cells by phagocytes in their vicinity (efferocytosis), a 
mechanism associated with protection against Mtb47,50. Indeed, arachidonate 5-lypoxigenase (ALOX5) 
deficient mice, which are unable to produce LTB4 and LXA4 thus shifting the metabolic pathway towards 
PGE2 production, are more resistant to Mtb51. In contrast, LXA4 induces a necrotic phenotype in infected 
cells, which favors bacterial proliferation and infection of bystander cells, thus enabling the formation of 
new infectious foci14,47,50. The extent of the role of eicosanoids is not yet fully understood, but human studies 
highlight their relevance in TB. Specifically, polymorphisms in Alox5 and Lta4h (involved in LTA4 synthesis) 
increase susceptibility to TB52,53. From an immunological standpoint, PGE2 production has been shown to 
be induced by IL-1β, and in addition to its direct effects in the control of Mtb, it also plays a role in 
regulating the crosstalk between IL-1β and type-I IFN46,54,55.     
Type-I IFNs comprise IFN-α and IFN-β and have been associated with detrimental effects to the host during 
Mtb infection, both in humans and in the mouse model. Specifically, high severity of active TB correlates 
with high levels of circulating type-I IFNs and high levels of expression of genes induced by these 
cytokines46,56. Accordingly, mice deficient in the receptor for these cytokines show increased survival and 
lower bacterial burdens upon Mtb infection57,58. It has been suggested that type-I IFNs exert their detrimental 
role in TB by downregulating the production of IL-1β and IL-12, partially due to an increase in IL-10 and IL-
1β antagonist production45,54,55,59. A schematic of the crosstalk between these cytokines is proposed in Figure 
1. 
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Figure 1: The balanced IL-1β – eicosanoid – type-I IFN network. Mtb induces IL-1α/β and type-I IFN production. IL-1β 
activates cyclooxygenase-2 (COX-2) resulting in PGE2 production. PGE2 inhibits type-I IFN activity, favoring control of Mtb. Type-I 
IFN induces IL-10 and IL-1R antagonist, blocking IL-1β activity and favoring Mtb growth. Originally from Jon S. Friedland, Clinical 
Implications of Basic Research, The New England Journal of Medicine, 2014. 
The relevance of the immune network formed by IL-1β, eicosanoids and type-I IFNs has just begun to be 
explored, but it already presents itself as a good target for anti-TB therapy, with the possibility to be used in 
a patient-specific manner54,55. 
2.2.2.5. Chemokines 
In addition to cytokines, chemokines play a major role in building the inflammatory environment 
encountered in TB. These chemokines are predominantly composed by two distinct classes, defined by the 
presence of a C-C or C-X-C motif and a single receptor may be able to bind multiple chemokines60. This 
family of proteins is responsible for orchestrating the recruitment of leukocytes to the site of infection and 
subsequent migration to different organs60. In the mouse model, there are at least 34 chemokines reported 
to be differential expressed throughout Mtb infection60, attesting the complexity of the cell-recruitment 
dynamics encountered during infection. Resorting to gene deficient mice, a vast effort has been placed 
towards characterizing the role of individual chemokines and their receptors in the context of Mtb infection. 
Few of these studies have reported differences regarding bacterial burden, and when these differences 
were reported they are predominantly in mice deficient for a chemokine receptor60. Indeed, only few studies 
reported a role for individual chemokines, suggesting a redundant role for these molecules60–63. Specifically, 
these studies have reported that mice deficient in C-C chemokine ligand 2 (CCL2), a CCR2 ligand, have a 
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transient increase in lung bacterial burden after low-dose aerosol infection, accompanied by a decreased 
macrophage influx and accumulation of protective IFN-γ CD4+ T cells64. These findings are in line with the 
increased risk of developing TB presented by humans with a Ccl2 polymorphism65. A similar phenotype was 
observed in mice deficient in CCL5 (CCR1/CCR5 ligand), although in this case the transiently increased 
lung bacterial burden was associated with a delayed recruitment of CD11c+ myeloid cells and T cells66. 
Other studies have shown that mice deficient for CCR7 or its known ligands (CCL19/CCL21) have an 
impaired DC migration to the lymph node, and are consequently impaired in T cell induction, translating 
into a diminished control of Mtb67–70. Interestingly, the action of chemokines is not restricted to cell-migration 
between organs, as they also play a role in the location of immune cells within the inflammatory lesion. 
Specifically, mice deficient in CXCL13 (CXCR5 ligand) have been shown to be more susceptible to Mtb, not 
due to an overall change in the number of a specific cell type, but instead due to the location of T cells 
within the granuloma69. In this case, in the absence of CXCL13, T cells were unable to locate in close 
proximity to infected macrophages, thus leading to insufficient macrophage activation and subsequent Mtb 
growth69.  
Taken together, these studies point for a complex role of chemokines during infection, controlling temporal 
and spatial features of the formation and action of both innate and adaptive immunity.   
2.3. Adaptive immune response 
The activation of the innate immune response is crucial for the establishment of an adaptive immune 
response. It is known that 8-10 days after infection, antigen-presenting cells (APCs) carrying Mtb or Mtb 
molecules, mainly DCs, arrive at the lymph nodes14. Once in the lymph node, these cells will present Mtb 
molecules to naïve T cells, driving their differentiation and proliferation, and up to 5 days later these Mtb-
specific T cells reach the site of infection5,14. It has been extensively described in humans and mice that 
adaptive immune responses are absolutely required to control Mtb. Specifically, HIV patients with low 
CD4+ T cell counts quickly succumb to Mtb infection if not rapidly treated4,71,72. A similar outcome is 
observed in recombination activating gene (RAG) deficient mice, which are unable to produce B and T 
lymphocytes and quickly succumb to Mtb shortly after infection73. 
There are two main CD4+ adaptive immune responses involved in TB, the T helper 1 (Th1) and Th17 
responses. These responses are generated when APCs present Mtb peptides in the context of a major 
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histocompatibility complex class 2 (MHC-II) to naïve CD4+ T cells in the presence of a specific cytokine 
milieu. For a CD4+ naïve T cell to acquire a Th1 phenotype it requires the expression of the transcription 
factor T-bet and IL-12 and IFN-γ as polarizing cytokines26,29,74,75. One the other hand, for optimal Th17 
polarization expression of the transcription factor retinoic acid receptor-related orphan receptor-γt (RORγt) 
is required, as well as the presence of IL-6,  transforming growth factor-β (TGF-β), IL-1β and IL-2314,74,75. 
The currently accepted paradigm is that a Th1 cell response must be induced for the host to control an 
otherwise lethal Mtb infection10,11,76. The Th1 cell subset is mainly characterized by the production of IFN-γ, 
which activates macrophages leading to the production of reactive nitrogen and oxygen species (RNS and 
ROS) 10,11,14,77–80. In the mouse model, the onset of a Th1 cell adaptive immune response leads to the 
stabilization of bacterial burden10,11,14. Indeed, mice deficient for IFN-γ, NOS2 or MHC-II are unable to control 
bacterial growth and rapidly succumb to infection77,81,82. Although the Th1 cell subset is clearly essential for 
the host’s protection, it is not able to sterilize the infected, even after boosting this response with the 
currently available vaccine. 
To a lesser extent, the Th17 cell subset also plays a role in the immune response to Mtb. This subset 
secretes mainly IL-17 which is known to modulate granuloma formation and is required for BCG vaccine-
dependent accelerated recruitment of IFN-γ producing T cells to the site of infection83,84. However, it has 
been shown that repeated BCG exposure of Mtb-infected mice leads to increased Th17 cell responses 
accompanied by neutrophil/granulocyte recruitment and consequently increased immunopathology due to 
enhanced neutrophilia85. Thus, although the induction of a Th17 response is largely benign in the context of 
TB, a tight regulation is required to avoid immunopathological consequences to the host83.  
During the immune response in TB, both Th1 and Th17 cell subsets are active and it is likely that a fine 
balance between them is required for a better outcome of TB. In this regard, it is known that Th1 cells are 
able to act as a negative regulator of the Th17 response by limiting neutrophil recruitment and 
downregulating IL-17 expression73, thus limiting excessive immunopathology. On the other hand, IL-17 is 
able to anticipate the recruitment of Th1 cells, thus improving resistance to infection86. The mechanisms 
through which the host and Mtb regulate these different subsets of Th cells are not fully understood. It is 
possible that the key to a more efficient vaccine lies in finding the right balance between Th1 and Th17 
cells.  
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The immune response in TB is a vast field of study, and although numerous works have helped to shed 
light on the matter, we are still unaware of the full spectrum of the mechanisms that govern this response 
and most importantly if there is an immune response capable of completely eliminating the pathogen. A 
simplified version of current knowledge regarding the cellular immune response to Mtb after low-dose 
aerosol infection is depicted in Figure 2.  
 
 
Figure 2: The cellular immune response to Mtb. After aerosol infection, Mtb can be phagocytosed by DCs, alveolar 
macrophages and neutrophils. Alveolar macrophages secrete inflammatory mediators including IL-1, IL-12p40, IL-6 and 
chemokines and together with neutrophils may die an apoptotic or necrotic cell death. DCs migrate to the draining lymph-node 
8-12 days after infection, under the influence of CCL2, CCL19, CCL21, IL-12p80 (IL-12(p40)2) and IL-12P70. Th1 cells are 
generated upon antigen presentation in the presence of IL-12p70. Th1 cells migrate to the lung 14-17 days after infection under 
the influence of CCL2, CCL19 and CCL21. Upon arrival to the lung, Th1 cells required IL-12p70 for maintenance and activate 
macrophages by secreting IFN-γ. These macrophages increase in microbicidal activity by upregulating NOS2 (iNOS), TNF-α and 
IL-12p40 production. Adapted from Anne O’Garra, et al., The Immune Response in Tuberculosis, Annual Reviews of 
Immunology, 2013. 
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3. Host-pathogen interactions 
The events that take place in the immune response during TB are the result of a complex interaction 
between the host and Mtb. A great portion of the work performed on deciphering this immune response 
has focused on characterizing host factors, often disregarding how pathogen factors modulate this 
response. Indeed, our knowledge on how Mtb is able to subvert and thrive under the seemingly unfavorable 
conditions found within the host is still unclear. To fully understand the intricate relationship between Mtb 
and humans, the only host known for Mtb, we must consider that both have been coevolving since the 
appearance of anatomically modern humans about 70 000 years ago87. This time frame has given both 
host and pathogen ample opportunity to fine tune their defense and virulence mechanisms, respectively, to 
one another87. Indeed, the fact that TB presents a wide range of outcomes, ranging from clearance after 
infection, to establishment of subclinical latent disease and ultimately to active disease attests to the 
complexity of TB1,4,14. Remarkably, for extended periods of time in active TB, the balance between a 
protective and detrimental immune response allows the host to remain ambulatory, thus increasing the 
opportunity for Mtb to be transmitted5. These different outcomes may be largely defined by the result of the 
initial interaction between Mtb and innate immune cells1. Accordingly, it has been shown that different 
strains of Mtb induce different inflammatory profiles after infection of these cell types88–91.    
3.1. The cell wall of Mtb and its impact in host-pathogen interactions  
The initial interactions between Mtb and the host are predominantly dependent of recognition of antigens 
present of the cell wall of Mtb by the PRRs on innate immune cells. This cell wall is an extremely complex 
structure, composed by 4 distinct layers: the innermost polysaccharide layer composed by peptidoglycans 
and arabinogalactan; the inner mycomembrane composed of long chain mycolic acids covalently attached 
to the innermost proteins; the outer mycomembrane composed many non-covalently lipids, including 
phthiocerol dimycocerosates (PDIMs); trehalose dimycolate (TDM); sulfolipids (SLs); 
phosphatidylinositolmannosides (PIMs) modified into lipomannans (LM) and lipoarabinomannans (LAM); 
glucose monomycolate (GMM); lipooligosaccharides (LOS); and the outermost capsular layer containing 
poorly characterized glycans, lipids and proteins92,93. A simplified schematic representation of the cell 
envelope of Mtb is depicted below in Figure 3. 
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Figure 3: Schematic representation of the cell envelope of Mtb. The cell wall is mainly composed by a large complex 
that contains three different covalently linked structures (peptidoglycan (grey), arabinogalactan (blue) and mycolic acids (green)). 
The outer mycomembrane contains various free lipids non-covalently linked to mycolic acids. These free lipids include TDM, 
PDIMs, SLs, LOS, GMMs, PIMs and its glycoconjugates. The capsule contains poorly characterized glycans, lipids and proteins. 
Adapted from Abdallah M. Abdallah, et al., Type-VII secretion – mycobacteria show the way, Nature Reviews Microbiology, 
200794.  
These lipid components of the outer mycomembrane and capsular layer are thought to be in direct contact 
with the host’s cells and therefore their study is important to understand how their recognition modulates 
the immune response16.  
As a result of the availability of the Mtb genome, and upon the development of efficient techniques to 
genetically manipulate this pathogen95,96, the employment of gene-deficient Mtb has allowed us to assess 
the role of specific Mtb molecules during infection. Particularly, this has allowed us to gain insight on the 
role of the relevance the Mtb cell wall lipids in infection. 
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3.1.1. TDM 
Among Mtb cell wall lipids, TDM is one of the most studied. This lipid is recognized by Mincle (a C-type 
lectin) and has been consistently associated as a virulence factor o Mtb15. Specifically, WT mice infected 
with a Mtb strain deficient for an enzyme responsible for adding distal-oxygen groups to mycolates 
presented increased survival when compared to mice infected with the WT strain97. In subsequent studies, 
this phenotype was attributed to an increased induction of IL-12p40 and TNF-α by the mutant strain98–100. 
Indeed, mice deficient for IL-12p40 presented the same survival time, regardless of the infecting Mtb 
strain98. 
3.1.2. PDIMs 
PDIMs were first reported to be a virulence factor upon the observation that Mtb clinical isolates deficient 
for PDIMs were unable to induce a severe disease in the ginea pigs101. More recently, it has been reported 
that PDIM-deficient Mtb induces a hyper inflammatory profile in macrophages, putatively due to higher 
exposure of PAMPs8. Additional, studies have shown that PDIM-deficient Mtb has an impaired growth inside 
resting macrophages, although these studies reported opposing results regarding the role of PDIMs on 
phagosomal acidification102,103. Recently, work performed with Mycobacterium marinum in the zebrafish 
larvae model has elegantly shown that PDIMs exert a role in modulating the inflammatory environment 
towards a bacterium-permissive one8. Specifically, it was shown that by avoiding TLR detection, and without 
myeloid differentiation primary-response protein 88 (MyD88) activation, the bacterium is able to induce the 
recruitment of permissive macrophages to the site of infection8. These macrophages show a reduced NOS2 
activation and are therefore a better environment for bacterial replication8. Unfortunately, this mechanism 
cannot fully explain the role of PDIMs in Mtb, as an independent study using the mouse model of infection 
was unable to rescue the phenotype observed with PDIM-deficient Mtb, even when infecting IFN-γ, NOS2, 
MyD88 and CCR2 deficient mice104. This particular study has shown that the lower bacterial burden, 
observed in PDIM-deficient Mtb infected animals, is due to an increased bacterial death, and not a deficit in 
replication, early during infection104. The question of whether PDIMs grant virulence by subverting any 
specific immune mechanism, or whether it does so by granting sheer cell wall integrity remains to be 
elucidated. 
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3.1.3. SLs 
The role of SLs during infection has not yet been clearly defined, but they are suggested to relevant during 
infection since the cell wall composition of Mtb extracted from infected humans or animals is enriched in 
SLs when compared to the composition found in Mtb under culture conditions105. SLs are recognized by 
NOD2 and class A SRs15,106, and as an anionic molecule it has been shown that SL-deficient Mtb has 
decreased susceptibility to LL-37, a human cationic antimicrobial peptide (AMP), by reducing Mtb-AMP 
interactions107. Despite this, no discernible phenotype has been observed between mice and murine 
macrophages infected with either WT or SL-deficient Mtb. Despite the fact that no differences regarding 
bacterial burden were observed, mice and guinea pigs infected with the SL-deficient Mtb presented a 
longer survival time than those infected with WT strain108,109. Interestingly, it has been reported that SLs are 
preferentially uptaken by neutrophils leading to high ROS production110, a microbicidal mechanism that 
confers limited protection against Mtb. Whether SLs induce Mtb phagocytosis by neutrophils, a cell-type 
considered to be a permissive niche for mycobacterial growth14, has not yet been assessed. One possible 
factor that may have hindered the attempt to define a clear role to SLs in TB is that the Mtb mutants 
employed so far were deficient exclusively for the SL-1 family. However, it has recently been proposed that 
the SL-2 family actually accounts for the highest quantity of SLs in Mtb111, thus it is possible that by 
removing this predominant SL family more pronounced phenotypes may be discovered. 
3.1.4. Other cell wall lipids 
Although in vitro studies have provided compelling evidence that PIMs and its glycoconjugates are able to 
modulate recognition and phagosome maturation in macrophages112–114, only limited in vivo work performed 
with Mtb mutants engineered for these structures has been published. Specifically, only one study using 
the zebrafish larvae model reported that a Mycobacterium marinum strain deficient for an enzyme required 
for LAM/LM branching, resulted in impaired growth of the bacterium when compared to the WT strain115. 
Hence, the role for these molecules during infection remains to be elucidated. Similarly, this Mtb-mutant 
strategy is yet to be employed for the study of GMMs and LOS. 
It is now clear that Mtb has developed a cell wall capable of modulating the immune response of the host 
in its favor. The fact that these lipidic cell wall molecules are subject to modifications in saturation, chain 
length, cyclization among others with unpredictable effects92,93, further affirms the complexity of this 
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pathogen. The study of these host-pathogen interactions has just begun to scratch the surface of the 
intricacy beyond this timeless disease, but the employment of genetically engineered Mtb may prove a 
powerful tool to further advance this field of study.  
4. The role of Rv0101 in Mtb virulence 
The study of Mtb cell wall components has yielded valuable information on how host and pathogen 
interact, allowing for the choice of better targets for the future development of antimycobacterial drugs. 
However, there are still many unexplored Mtb molecules whose role during infection remains 
uncharacterized. Our knowledge on how the pathogen is able to thrive in the hostile conditions 
encountered inside the host could greatly benefit from the study of these molecules in the context of 
infection. Therefore, to advance this knowledge, we proposed to characterize a non-ribosomal peptide 
synthetase (nrp) encoded by Mtb, whose role during infection has not yet been defined.  
Nrp is coded by Rv0101, and is part of a larger operon comprising other five genes: Rv0096, a member of 
the Proline-Proline-Glutamic acid (PPE) family; Rv0097, an oxidoreductase; Rv0098, a type III thioesterase; 
Rv0099, a fatty acid adenosine monophosphate (AMPh) ligase and Rv0100, which encodes an acyl carrier 
protein116. Nrp is predicted to interact with Rv0099 and Rv0101 to form a multimodal enzyme 117 and is an 
ubiquitous protein, present in cytosol, cell membrane and cell wall fractions of H37Rv 118. Sequence 
analysis of the nrp gene predicts that this enzyme is involved in lipid metabolism 119. The function of nrp in 
lipid metabolism together with its localization in the cell wall, are good indications that this enzyme takes 
part in cell wall synthesis. 
Although so far no study has directly addressed the role of this enzyme, it has been mentioned multiple 
times in the literature as a potential Mtb virulence factor. Specifically, it was reported as a non-essential 
gene for in vitro growth by transposon mutagenesis, but was on the other hand required for growth in the 
spleen of C57BL/6J mice 119,120. Interestingly, nrp was reported to be the most abundant Mtb protein in the 
lungs of infected guinea pigs by day 30 post infection, while being undetected at 90 days post infection 121, 
suggesting that Mtb regulates the expression of this protein throughout the course of infection. Overall 
these reports point for a strong role of nrp during infection. 
Taking these data in consideration, in this present work we propose to characterize the relevance of nrp 
during infection, and how it impacts the interactions between Mtb and the host. 
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Mtb is arguably the most successful pathogen known to mankind, with its existence spanning as long as 
that of mankind. To once and for all eradicate TB, a greater understanding of the fine mechanisms by 
which the pathogen is able to survive and thrive inside its human host is required. Many potentially pivotal 
Mtb virulence factors remain either unknown or uncharacterized, and their study could benefit greatly the 
development of new vaccines and anti-mycobacterial therapies. 
 
The main goals of this thesis are to define the impact of nrp on: 
The growth of Mtb under optimal culture conditions. 
The interactions of Mtb with macrophages in an in vitro setting. 
The course of Mtb infection in the mouse model. 
The modulation of the innate and adaptive immune response of the host. 
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1. Bacteria and Infection  
Mtb ∆nrp-mutant and nrp-complemented strains, were generated on a H37Rv background by Dr Apoorva 
Bhatt (School of Biosciences – University of Birmingham). Bacteria were grown in Middlebrook 7H9 liquid 
media (BD Biosciences) for 7–10 days and then sub-cultured in Proskauer Beck (PB) medium, 
supplemented with 0.05% Tween 80 and 2% glycerol, to the mid-log phase. Bacterial stocks were aliquoted 
and frozen at –80°C. To determine the concentration of Mtb aliquots, 6 frozen aliquots were serial diluted 
and plated in Middlebrook 7H11 (BD Biosciences) agar plates supplemented with 10% oleic 
acid/albumin/dextrose/catalase (OADC) and 0.5% glycerol. Viable bacteria were determined by counting 
colony-forming units (CFUs) after 19-21 days of incubation at 37°C. 
Mice were infected via aerosol route using an inhalation exposure system (Glas-Col). Briefly, bacterial 
clumps were disrupted by forcing them through a 26G needle 6 times and diluted in water (Aqua B. Braun) 
to a concentration of 2x106 CFU/mL. Mice were exposed to the infectious aerosol for 40 minutes, resulting 
in the delivery of 100-200 viable bacteria to the lungs. Assessment of initial bacterial burden was 
performed 3 days post infection by growing viable bacteria from the whole lung homogenate of 5 mice. 
2. Animals 
C57BL/6 mice were purchased from Charles River Laboratory (Barcelona, Spain). RAG-2 and IFN-γ 
(generated on a C57BL/6 background) deficient mice were generously provided by Dr. Margarida Correia-
Neves (ICVS) and Dr. Susana Roque (ICVS), respectively. IL-10 (generated on a C57BL/6 background) 
deficient mice were a kind gift from Dr. Anne O’Garra (MRC-NIMR, London). ALOX-5, ALOX-15, TLR-2 and 
TLR-4 (generated on a C57BL/6 background) deficient mice were also purchased from Charles River 
Laboratory. All mice were kept and bred under the same conditions in the Life and Health Sciences 
Research Institute (ICVS) animal housing facilities, at the school of Health Sciences, University of Minho. All 
mouse protocols were performed according to the European Union Directive 2010/63/EU, and previously 
approved by Direcção Geral de Alimentação e Veterinária. 
3. Differentiation and Infection of Bone Marrow-Derived Macrophages (BMDM) 
and Peritoneal Macrophages 
Bone marrow cells were flushed from the tibiae and femurs of mice with complete Modified Eagle Medium 
(cDMEM, DMEM supplemented with 10% of heat-inactivated fetal bovine serum (FBS), 1% of HEPES 1M, 
1% L-glutamine and 1% sodium pyruvate 100mM (all from GIBCO)). Bone marrow cells were counted and 
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cultured in 8mL cDMEM supplemented with 20% L929-cell-conditioned medium (LCCM) at a concentration 
of 0.5 x 106 cells/mL in 8-cm diameter plastic petri dishes (Sterilin) for 7 days under 37°C and 5% CO2 
conditions. On day 4 of differentiation, 10mL of cDMEM supplemented with 20% LCCM were added to the 
cultures. At day 7, adherent cells were mechanically detached and seeded in 24-well plates (Nunc) at a 
concentration of 1x106/well and incubated at 37°C. Cells were infected with Mtb at a multiplicity of 
infection (MOI) of 1:1 (bacteria/macrophage ratio) and incubated at 37°C with 5% CO2. Four hours after 
infection, cells were washed 4 times with phosphate-buffered saline (PBS) (GIBCO) to remove extracellular 
bacteria. Washed cells were resuspended in 1mL of cDMEM and either incubated at 37°C for 48/96 
hours in the presence or absence of 100 U/mL of IFN-γ or used to determine bacterial internalization. For 
that, 0.1% saponin (Sigma-Aldrich) in PBS was added to the wells and the cells were incubated at RT for 10 
minutes to release intracellular bacteria. The number of viable bacteria was determined by plating 10-fold 
serial dilutions of the saponin treated cell suspensions in supplemented Middlebrook 7H11, as previously 
mentioned.  
Peritoneal macrophages were obtained by intraperitoneally injecting 1 mL of thioglycollate in wild-type (WT) 
C57BL/6 mice. After 4 days, mice were euthanized and the peritoneum washed with PBS. The number of 
cells of the obtained peritoneal macrophage-enriched cell suspension was counted and processed for 
infection as described above for BMDM. 
Supernatants from these cultures were used to determine nitric oxide concentration by the Griess method 
and cytokine concentration by ELISA. 
4. Sample Collection and Preparation of Single Cell Suspensions 
At selected time-points post-infection, mice were euthanized by CO2 asphyxiation and the organs aseptically 
excised. Lungs were perfused with 10 mL PBS through the right ventricle of the heart to flush blood cells, 
sliced with 2 sterile scalpels and incubated at 37ºC with collagenase IX (0.7mg/mL, Sigma-Aldrich) for 30 
minutes. Single cell suspensions from the spleen and digested lung were obtained by homogenized by 
sieving them through a 40-µm-pore-size nylon cell strainer (BD Biosciences) with a syringe plunger. Lung 
and spleen cells were treated with erythrocyte lysis buffer (0.87% of NH4Cl solution and 5% of PBS in 
water) to lyse red blood cells and resuspended in cDMEM to use for bacterial burden determination, flow 
cytometry analysis and RNA extraction. Single cell suspensions were counted using a Countess® 
Automated Cell Counter (Life Technologies). 
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5. Survival  
RAG-2 and IFN-γ deficient mice infected with Mtb weight was determined before infection and every 48 
hours from day 30 post-infection onward. Mice were euthanized when they lost 20% weight or upon losing 
responsiveness to physical stimulation. Whenever possible, the lungs of moribund animals were harvested 
for histology and bacterial burden assessment. 
6. Bacterial Burden Determination 
To determine bacterial burdens, lung and spleen single cell suspensions were incubated with 0.1% saponin 
(Sigma-Aldrich) for 10 min to release intracellular bacteria. The number of CFUs was determined by plating 
10-fold serial dilutions of saponin-treated cell suspensions in Middlebrook 7H11 agar plates supplemented 
as described above. BBL™ MGIT™ PANTA™ antibiotic mixture (BD Bioscience) was added to prevent 
contaminations of lung samples. Viable Mtb colonies were counted after 19-21 days of incubation at 37ºC. 
7. Histology  
The right upper lobe of the lung was inflated with 5 mL of PBS containing 3.7% formaldehyde and kept for 
1 week in this solution. Afterwards, these lobes were embedded in paraffin, sectioned in 2-3μm thickness 
slices, and stained with hematoxylin- eosin (H&E). 
8. Flow Cytometry 
For surface staining 1-2x106 cells were washed with FACS buffer (PBS containing 2% FBS and 0.01% azide) 
and stained for surface antigens for 30 minutes at 4°C. Cells were washed with FACS buffer and PBS and 
then fixed overnight (ON) in PBS containing 2% paraformaldehyde. The following antibodies were used: 
CD4-PB (clone RM4-5, eBioscience), CD8-FITC (clone 5H10-1, Biolegend), CD44-PerCPCy5.5 (clone 1M7, 
eBioscience), CD62L-PECy7 (clone MEL-14, Biolegend, Ly6G-APC (clone 1A8, Biolegend), MHC II-FITC 
(clone AMS-32.1,BD Pharmingen), Ly6C-PerCPCy5.5 (clone AL-21,BD Pharmingen), CD11b-PE (clone 
M1/70 from Biolegend), CD11c-PB (clone N418, Biolegend). Samples were acquired on a LSRII flow 
cytometer with Diva Software. All data were analyzed using FlowJo version 7.6.5 software. A schematic of 
the gating strategy performed is depicted below in Figure 4.  
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Figure 4: Cytometry analysis. Gating strategy for A) lymphoid cells and B) myeloid cells. 
The total number of cells in each gate was calculated using the total number of cells determined by 
Countess® Automated Cell Counter. 
 
9. Mtb growth curves 
H37Rv WT, nrp-complemented and ∆nrp mutants were inoculated in 40mL of either 7H9 with 10% OADC 
or PB medium at an initial OD of 0.002 at 570nm. The cultures were grown in ventilated Erlenmeyers 
(Cole-Parmer) at 37°C and 120 rpm. Every 48 hours a sample of each culture was used for OD 570nm 
readings.    
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10. Cytokine concentration by Enzyme-Linked Immunosorbent Assay (ELISA)  
The concentration of TNF-α, IL-1β and IL-10 in the supernatants was determined by using the 
commercially available ELISA kit for IL-10 (88-7104), IL-1β (88-7013) and TNF-α (88-7324), all from 
eBioscience, according to the manufacturer’s instructions. 
11. RNA extraction and quantification  
Total RNA from cell suspensions was extracted by using TRIzol® Reagent (Invitrogen, San Diego, CA) 
according to the manufacturer’s instructions. Briefly, glycogen (20μg/μl from Roche) was added to each 
sample and incubated for 5 minutes at RT. After incubation, 50μl of chloroform (Sigma-Aldrich) were 
added and the samples were mixed by vortexing and incubated on ice for 15 minutes. Afterwards, samples 
were centrifuged at 13000 rpm for 15 minutes at 4°C, and the upper aqueous phase was carefully 
recovered, and mixed with an equal volume of isopropyl alcohol (Sigma-Aldrich) to precipitate the RNA. 
Samples were incubated ON at -20°C and centrifuged at 13000 rpm for 15 minutes at 4°C. The 
supernatant was removed and the pellet washed with 800μl of 70% ethanol (Carlo Erba reagents). Ethanol 
was completely removed after centrifugation at 9000 rpm for 5 minutes and the dried RNA pellet was 
resuspended in RNase/DNase-free water (Gibco). RNA concentration was measured at 260nm (Nanodrop 
ND-1000 Spectrophotometer) and the purity assessed through the A260/A280 and A260/A230 ratios. 
12. Reverse transcriptase polymerase chain reaction (RT-PCR) 
Complementary DNA (cDNA) was synthesized using the GRS cDNA Synthesis Mastermix Kit (GRISP) 
according to the manufacturer’s instructions. Briefly, reaction mix was composed by 10μl of GRS RT 
Mastermix, 1μl of oligo(dT)20 and 9μl of RNA sample mixed with nuclease-free water. The cDNA synthesis 
reaction was performed in thermocycler (MyCycler, Bio-Rad) with the following program: 25°C for 10 
minutes followed by 10 minutes at 42°C and 5 minutes for 85°C. The resultant cDNA template was used 
for quantification of target genes expression by real-time PCR (RT-PCR) analysis using SYBR green or 
TaqMan detection systems. 
13. Quantitative Real-Time PCR (qRT-PCR)  
For SYBR Green reactions 1µL of each cDNA sample was mixed with 9µL of reaction mix containing 3µL of 
water, 1µL of 0.4µM forward and reverse specific primer and 5µL of SYBR green qPCR Master Mix 
(GRISP). RT-PCR was performed in CF*96TM Real-time system (Bio-Rad) using the following program: 
95°C for 15 minutes, followed by 40 amplification cycles of 95°C for 3 seconds, 60°C for 20 seconds and 
 
 
28 
 
70ºC for 15 seconds, for melting curve analysis. For TaqMan reactions 1µL of each cDNA sample was 
mixed with 9µL of reaction mix containg 3.5µL of water, 0.5µL of specific primer-probes and 5µL of 
TaqMan Gene Expression Master Mix (Applied Biosystems). The RT-PCR program used was 50°C for 2 
minutes, 95ºC for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Relative mRNA 
expression of the target gene was normalized to the levels of the housekeeping gene using the ∆Ct 
method: 1.8^(Housekeeping gene mRNA expression – Target gene mRNA expression) x 100000. The 
sequences of primers and references of the TaqMan primer-probe sets used in RT-PCR are listed in Table 
1.  
 
Table 1: Sequences of SYBR Green primers and TaqMan primer-probes used. 
 
SYBR Green 
primers 
Forward Reverse 
Ubiquitin 5’-TGGCTATTAATTATTCGGTCTGCAT-3’ 5’-GCAAGTGGCTAGAGTGCAGAGTAA-3’ 
TNF-α 5’- GCCACCACGCTCTTCTGTCT-3’ 5’- TGAGGGTCTGGGCCATAGAAC -3’ 
IFN-γ 5’-CAACAGCAAGGCGAAAAAGG-3’ 5’-GGACCACTCGGATGAGCTCA-3’ 
IL-1β 5’-TGTAATGAAAGACGGCACACC-3’ 5’-TCTTCTTTGGGTATTGCTTGG-3’ 
 
TaqMan Primer-Probes 
HPRT Mm.299281 
CCL2 Mm.441242 
CCL7 Mm.443113 
 
14. Statistical Analysis 
Data were analyzed using GraphPad Prism 6. Depending on the nature of the dataset, differences between 
groups were analyzed using Student’s t-Test or Two-way ANOVA using Sidak’s test for multiple 
comparisons. Survival curves were compared using the Log-rank (Mantel-Cox) test. Differences were 
considered significant for p≤0.05 and represented as follows: *p≤0.05;**p≤0.01;***p≤0.001 and 
****p≤0.0001. 
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1. Initial considerations 
 
The ∆nrp mutant and the nrp-complemented strain were generated on a H37Rv background by our 
collaborator Dr. Apoorva Bhatt (School of Biosciences, University of Birmingham). Our collaborator is 
currently characterizing the biochemical and functional properties of nrp. From a microbiological 
standpoint, we have only assessed whether nrp was required for optimal Mtb growth under normal culture 
conditions. We found no significant differences in growth kinetics between Mtb strains in either PB or 7H9 
liquid medium (Figure 5). 
 
Figure 5: nrp-complemented and ∆nrp-mutant strains growth kinetics in liquid media. Biomass over time measured 
by optic density at 570nm in A) 7H9 and B) PB inoculated with either nrp-complemented or ∆nrp-mutant strains. Culture media 
were inoculated with either Mtb strain at a theoretical OD570nm value of 0.002. Average doubling time in hours (nrp-
complemented vs ∆nrp-mutant) was 25.15 vs 24.79 in 7H9 medium and 34.92 vs 34.08 in PB medium.  
 
Thus, we focused on characterizing the relevance of this protein in the context of infection. To achieve this 
goal we took advantage of the mouse model infected via the aerosol route previously established in our 
laboratory. From these animals we assessed survival and bacterial burdens, gene expression as well as 
immunopathology in specific organs throughout the course of infection. We have also resorted to infecting 
macrophages from different origins to further elucidate innate interactions between host cells and 
pathogen. Overall this experimental setup has allowed us to better understand the role of nrp in the context 
of infection. 
A B 
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2. In vivo infection 
2.1. Nrp is required for optimal establishment of infection  
To assess the relevance of nrp during infection, we started by infecting via the aerosol route WT C57BL/6 
mice with either ∆nrp-mutant or nrp-complemented strains. Bacterial burdens in the lung and spleen were 
analyzed at different time-points throughout infection (Figure 6A and 6B). Our data showed a difference 
regarding lung bacterial burden by day 20 post-infection between Mtb strains expressing or not Nrp (Figure 
6A). Specifically, animals infected with the ∆nrp-mutant strain presented on average a 48-fold lower 
bacterial burden (1.683 Log10 average difference) when compared to those infected with the nrp-
complemented strain.  
We have also observed differences regarding bacterial burdens in the spleen of infected animals (Figure 
6B). In this organ we were unable to detect Mtb before day 30 post-infection in animals infected with the 
∆nrp-mutant. Moreover, the bacterial burden shown at day 30 post-infection in these animals remained 
stable (≈ 3.25 Log10) throughout the time period assessed, significantly lower than the one observed in 
animals infected with the nrp-complemented strain.     
 
 
 
 
 
 
Figure 6: Animals infected with the ∆nrp-mutant or the nrp-complemented strain presented different bacterial 
burdens over time in the lungs and spleen. A) Lung bacterial burden differs between Mtb strains at day 20 between ∆nrp 
and complemented strain (average 3.867 vs 5.550 Log10 bacterial burden, respectively). B) Spleen bacterial burden in ∆nrp-
mutant infected mice was lower for every time-point assessed when compared to mice infected with the nrp-complemented 
strain. Data analyzed performing a Two-way ANOVA using Sidak’s test for multiple comparisons. BDL – Below detection 
level.**** p<0.0001 *** p<0.001; **p<0.01. Each time-point contains pooled data from 2 separate experiments with 5 animals 
each. Initial bacterial burden for animals infected with the ∆nrp-mutant and the nrp-complemented strain were 1.860±0.0446 
Log10 and 1.931±0.0822 Log10, respectively. 
A B 
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Taken together, these data suggest that nrp is required for Mtb to efficiently colonize the host lungs during 
early stages of infection in addition to potentiate early dissemination events or facilitating the growth of Mtb 
in different microenvironments, such as those found in the spleen.  
2.2. Nrp induces lung immunopathology 
In addition to the differences observed regarding bacterial burdens, a discernible phenotype was also 
observed in lung histopathological features throughout infection (Figure 7A). In this matter, H&E 
histological preparations from the lungs of animals infected with either the ∆nrp-mutant of the nrp-
complemented strain at different time-points throughout infection revealed differences regarding the onset 
of pathology and the extension of lesions. Specifically, by day 20 post-infection no discernible lesions were 
observed in the lungs of ∆nrp-mutant infected animals, whereas multiple small inflammatory infiltrates 
were already present in the lungs of animals infected with the nrp-complemented strain (Figure 7). This 
difference was likely due to the differences in bacterial burdens at this time-point (Figure 6A). By day 30 
post-infection, lesions in the lungs of mice infected with the nrp-complemented strain were larger than its 
∆nrp-mutant counterpart, even though both presented the same bacterial burden (Fig 6A). Remarkably, 
these differences were kept during the chronic stage of infection. Indeed, on day 90 post-infection animals 
infected with the nrp-complemented strain still presented a greater degree of pathology than those infected 
with the ∆nrp-mutant (Figure 7), despite the fact that bacterial burdens had been similar in both cases for 
60 days (Figure 6A). 
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Figure 7: Animals infected with the ∆nrp-mutant or the nrp-complemented strain presented different 
immunopathology in the lungs. H&E stained lung preparations magnified 40X. Initial bacterial burden for animals infected 
with the ∆nrp-mutant and the nrp-complemented strain were 1.860±0.0446 Log10 and 1.931±0.0822 Log10, respectively. 
 
Quantification of the percentage of the lung section presenting an inflammatory infiltrate substantiated 
these observations (Figure 8A), as this area was always higher in mice infected with the nrp-complemented 
strain than in those infected with the ∆nrp-mutant. Furthermore, translating these areas into a previously 
described histopathological score for lung infection in the mouse model122 upheld the same differences 
(Figure 8B).  
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Figure 8: Characterization of H&E preparations from the lungs of animals infected with the ∆nrp-mutant or the 
nrp-complemented strain revealed differences in immunopathology. A) Percentage of lesioned lung area in mice 
infected with either ∆nrp-mutant or nrp-comp Mtb strains. B) Lung histopathological score based on the percentage of lesioned 
lung area. Data analyzed performing a Two-way ANOVA using Sidak’s test for multiple comparisons. BDL – Below detection 
level. **** p<0.0001; **p<0.01. Each time-point contains pooled data from 2 separate experiments with 5 animals each. Initial 
bacterial burden for animals infected with the ∆nrp-mutant and the nrp-complemented strain were 1.860±0.0446 Log10 and 
1.931±0.0822 Log10, respectively.  
 
Taken together our data indicate that in the absence of nrp, mice are at least equally able to control 
infection, doing so with less immunopathology. This suggests that a differential immune response is 
occurring in the absence of nrp. In turn, this response could account for the lower bacterial burden at day 
20 post-infection and the overall lower lung immunopathology observed in mice infected with the ∆nrp-
mutant, when compared to those infected with the nrp-complemented strain. To assess this hypothesis we 
proceeded to quantify and characterize by flow cytometry some of the key cell types involved in the 
immune response to Mtb. 
 
 
 
 
2.3. Immune response characterization 
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2.3.1. Nrp modulates the cellular immune response  
 
To investigate the hypothesis that distinct immune responses are elicited in the host depending on Mtb 
expressing Nrp or not, we started by analyzing by flow cytometry the dynamics of the different immune cell 
types in the lungs of infected animals. For this analysis we focused on cells from myeloid and lymphoid 
origin known to be relevant to the pathogenesis of TB. Accordingly, we assessed different types of 
phagocytes and CD4+ T cells, as well as some of their activation markers.  
By day 20 post-infection, animals infected with the nrp-complemented strain presented an average 5.93-
fold higher number of inflammatory monocytes, as defined by the surface markers CD11b+Ly6ChiLy6G-, 
than their ∆nrp-mutant infected counterparts (Figure 6B). Furthermore, these cells presented a higher 
activation status on nrp-complemented infected animals, as seen by the expression of MHC-II on their 
surface (Figure 9C). On average, 34.79% of these cells present surface MHC-II class molecules, whereas 
only an average of 3.41% of inflammatory monocytes from mice infected with the ∆nrp-mutant display this 
marker (data not shown). At day 30 post-infection these differences were attenuated, but were still 
significant (Figure 9B and 9C). We have observed no significant differences regarding neutrophils, as 
defined by the surface markers CD11b+Ly6CintLy6Ghi, in any time-point assessed (Figure 9D).  
 
 
 
 
 
 
 
 
 
37 
 
 
 
Figure 9: The ∆nrp-mutant and nrp-complemented 
strain induced different myeloid cell recruitment in 
the lungs of WT mice. A) Contour plots for SSC-A/CD11b 
and Ly6C/Ly6G including gating strategy. Initially CD11b 
positive cells ploted against SSC-A were selected. Afterwards, 
inflammatory monocytes (Ly6ChiLy6G-) and neutrophils 
(Ly6CintLy6Ghi) were selected. Total number of B) 
inflammatory monocytes, C) MHC-II positive inflammatory 
monocytes and D) neutrophils in the lungs of mice infected 
with either ∆nrp or nrp-comp Mtb strains by days 20 and 30 
post infection. Data analyzed performing a Two-way ANOVA 
using Sidak’s test for multiple comparisons. **** p<0.0001; 
***p<0.001; *p<0.05. Each time-point contains pooled data 
from 2 separate experiments with 5 animals each. Initial 
bacterial burden for animals infected with the ∆nrp-mutant 
and the nrp-complemented strain were 1.860±0.0446 Log10 
and 1.931±0.0822 Log10, respectively. 
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In contrast with inflammatory monocytes and neutrophils that are recruited to the infected tissue, no 
differences were observed regarding the resident population of alveolar macrophages, as defined by the 
surface markers CD11chiCD11blow (Figure 10B).  
 
  
Figure 10: Total number of alveolar macrophages was independent of infecting strain. A) Contour plots for 
CD11c/CD11b including gating strategy. Gating was performed on CD11chiCD11bint. B) Total number of alveolar macrophages 
in the lungs of mice infected with either ∆nrp or nrp-comp Mtb strains by days 20 and 30 post-infection. Data analyzed 
performing a Two-way ANOVA using Sidak’s test for multiple comparisons. Each time-point contains pooled data from 2 separate 
experiments with 5 animals each. Initial bacterial burden for animals infected with the ∆nrp-mutant and the nrp-complemented 
strain were 1.860±0.0446 Log10 and 1.931±0.0822 Log10, respectively. 
 
Analysis of CD4+ lymphocytes revealed differences regarding both total number and activation status. 
Specifically, and although non-significant, by day 20 post-infection the lungs of animals infected with the 
nrp-complemented strain presented higher numbers of CD4+ T cells (≈ 2-fold) than those infected with the 
∆nrp-mutant (Figure 11B). This trend was also translated in total number of activated CD4+ lymphocytes 
(Figure 11C), defined by the surface markers CD4+CD44+CD62L-, as animals infected with the nrp-
complemented strain presented higher numbers of this cell type than those infected with the ∆nrp-mutant 
(average 4-fold difference). By day 30 post-infection we observed significant differences between these cell 
types depending on the infecting Mtb strain (Figure 11). In this regard, animals infected with the nrp-
complemented strain presented approximately 2.25 times more CD4+ T cells and 2.84 times more 
activated CD4+ T cells than animals infected with the ∆nrp-mutant.  
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Figure 11: The ∆nrp-mutant and nrp-complemented strains present different CD4+ T cell features in the lungs 
of WT mice. A) Contour plots for CD4/CD8 and CD44/CD62L including gating strategy. Initially CD4 positive cells ploted 
against CD8 were selected. Afterwards, activated lymphocytes (CD44hiCD62L-) and non-activated lymphocytes (CD44-CD62Lhi) 
were selected. B) Total number of CD4+ T cells and C) activated CD4+ lymphocytes in the lungs of mice infected with either 
∆nrp or nrp-comp Mtb strains by days 20 and 30 post-infection. Data analyzed performing a Two-way ANOVA using Sidak’s test 
for multiple comparisons. **** p<0.0001. Each time-point contains pooled data from 2 separate experiments with 5 animals 
each. Initial bacterial burden for animals infected with the ∆nrp-mutant and the nrp-complemented strain were 1.860±0.0446 
Log10 and 1.931±0.0822 Log10, respectively. 
 
Taken together, the cytometry data suggest that expression of nrp by Mtb induces a stronger immune 
response, since in its presence most cell types involved in the immune response against Mtb are present in 
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higher numbers and with a higher activation status throughout infection. Nevertheless, this vigorous 
immune response does not appear to be beneficial for the host, since it is not translated into a better 
control of Mtb and is actually accompanied by enhanced immunopathology. Indeed, in the absence of nrp, 
a milder immune response seems to be better able to control Mtb up to day 30 post-infection. This 
phenotype raises the question of how nrp orchestrates the mounting of an immune response to the 
advantage of Mtb and how this response differs in terms of key molecular agents in the absence of nrp. To 
address this issue we assessed the expression of several molecules relevant in the immune response 
against Mtb. 
2.3.2. Cytokine and chemokine expression is modulated by nrp 
To clarify the differences observed regarding cell numbers, we chose to analyze the chemokines CCL2 and 
CCL7, as these are known to play a role in recruitment of immune cells to the site of infection and in 
assisting the triggering of an adaptive immune response60. Moreover, to elucidate whether nrp induces 
functional differences in the immune response, other than cell numbers, we assessed the expression of 
TNF-α, IL-1β, IFN-γ, NOS2 and IL-17 at the site of infection.  Among these, TNF-α, IL-1β and IFN-γ are 
essential to fully activate the host microbicidal mechanisms and NOS2 is responsible for the production 
RNS, one of the main defense mechanisms against Mtb. Additionally, we also examined IL-17 expression, 
as differences in this cytokine may reflect a differential polarization of T cells between the Th1 and Th17 
phenotype. 
Interestingly, Ccl2 expression was lower in animals infected with the ∆nrp-mutant by day 20 post-infection 
than in animals infected with the nrp-complemented strain (Figure 12A). This chemokine is responsible for 
the recruitment of myeloid cells to the site of infection, especially monocytes and DCs. Furthermore, it also 
plays a role on the migration of APCs to the lymph node, therefore contributing to the generation of an 
adaptive immune response5. The fact that the expression of this chemokine was reduced in animals 
infected with the ∆nrp-mutant by day 20 post-infection is in line with the lower number of inflammatory 
monocytes and CD4+ lymphocytes present, when compared to animals infected with the nrp-
complemented strain (Figure 9B and 11). On the other hand, the relative expression levels of this 
chemokine shifts by day 30 post-infection. In this case, ∆nrp-mutant infected mice expressed higher levels 
of CCL2 when compared with their nrp-complemented infected counterparts. This increase in Ccl2 
coincides with an increased recruitment of inflammatory monocytes to the lungs of ∆nrp-mutant infected 
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mice.  Although not significant, a similar profile of expression was observed for Ccl7 (Figure 12B), a close 
relative of Ccl2, which may therefore contribute to the lower levels of inflammatory monocytes observed in 
the lungs of mice infected with the ∆nrp-mutant.  
Interestingly, and despite the 48-fold lower bacterial burden observed in animals infected with the ∆nrp-
mutant by day 20 post-infection, when compared to nrp-complemented infected mice, there appears to be 
no difference on the expression levels of Tnf and Il1b (Figure 12C and 12D). A possible scenario is that the 
∆nrp-mutant activates the innate immune cells to induce higher levels of these cytokines. This would 
explain why despite the lower bacterial burden by day 20, mice infected with the ∆nrp-mutant expressed 
similar levels of these cytokines when compared to mice infected with the nrp-complemented strain. By day 
30, mice infected with the ∆nrp-mutant express lower levels of Il1b and higher levels of Tnf when 
compared to mice infected with the nrp-complemented strain.  
Finally, the lung expression of Ifng (Figure 12E) on day 20 post-infection was lower for the ∆nrp-mutant 
than for the nrp-complemented strain. These differences subsided by day 30 post-infection. At this time-
point, IFN-γ expression reached similar levels to those observed in animals infected with the nrp-
complemented strain on day 20 post-infection. As previously mentioned, the expression of Nos2 and Il17 
were also assessed, but no measureable amplification was observed in either time-point assayed. 
Taken together, these gene expression assays revealed that expression of nrp during infection induced the 
recruitment of innate immune cells likely in a CCL2, and to a lesser extent CCL7, dependent-way. 
Furthermore, nrp expression also led to a differential activation of immune cells, as seen by the distinct 
expression of Tnf and Il1β between animals infected with Mtb expressing nrp or not. Lastly, nrp also 
appeared to anticipate the onset of a Th1 response, as seen by the earlier expression of IFN-γ in animals 
infected with the nrp-complemented strain. 
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Figure 12: The ∆nrp-mutant and nrp-complemented strain induced differential cytokine/chemokine expression 
in the lungs of WT mice. Expression of A) Ccl2 B) Ccl7 C) Il1β D) Tnf and E) Ifnγ relative to Hprt in the lungs of mice 
infected with either ∆nrp-mutant or nrp-complemented Mtb strains by days 20 and 30 post-infection. Data analyzed performing 
a Two-way ANOVA using Sidak’s test for multiple comparisons. *** p<0.001; **p<0.01;*p<0.05. Each time-point contains 
pooled data from 2 separate experiments with 5 animals each. Initial bacterial burden for animals infected with the ∆nrp-mutant 
and the nrp-complemented strain were 1.860±0.0446 Log10 and 1.931±0.0822 Log10, respectively. 
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2.3.3. Nrp is required for full virulence in mouse models of deficient adaptive 
immunity 
Taking into consideration that, in WT mice, differences in bacterial burden were only detected on day 20 
post-infection, a period of time where the immune response is predominantly innate, we next investigated 
the contribution of the adaptive immune response in the context of infection with Mtb expressing or not 
nrp. For this purpose, we infected RAG-2 deficient mice, which are unable of generating B and T 
lymphocytes, and IFN-γ deficient animals, which lack the expression of IFN-γ a key protective mechanism 
against Mtb.  
RAG-2 deficient animals are unable to control Mtb growth and typically succumb to infection 40 to 50 days 
after infection 73. Accordingly, RAG-2 deficient mice infected with the nrp-complemented strain showed an 
average survival of 44.7 days (Figure 13A). Interestingly, RAG-2 deficient mice infected with the ∆nrp-
mutant presented an average survival of 114 days post-infection (Figure 13A). These data clearly point nrp 
as a virulence factor. We also followed the bacterial burdens of RAG-2 deficient animals at different stages 
of infection (Figure 13B). Consistently with the absence of an adaptive immune response the bacterial 
burden in the lungs of RAG-2 deficient animals infected with Mtb expressing or not nrp kept increasing over 
time. Specifically, lung bacterial burden in RAG-2 deficient animals infected with the nrp-complemented 
strain or the ∆nrp-mutant increased steadily until reaching an average of 8.01 Log10 and 8.29 Log10, 
respectively, before succumbing to infection (Figure 13B). Additionally, without the control provided by an 
adaptive immune response, RAG-2 deficient animals infected with the nrp-complemented strain presented 
a higher bacterial burden from day 20 onward than those infected with the ∆nrp-mutant.   
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Figure 13: The ∆nrp-mutant presented reduced virulence in RAG-2 deficient mice. A) Survival curve of RAG-2 
deficient mice infected with either the nrp-complemented strain or ∆nrp-mutant, using 10 animals per strain. B) Bacterial 
burden over time of RAG-2 deficient infected with either Mtb strain. Terminal bacterial burden ploted on the average survival time 
and marked with a black cross. Each time-point contains data from 5 animals. ****p<0.0001. ns – non-significant. Initial 
bacterial burden for animals infected with the ∆nrp-mutant and the nrp-complemented strain were 1.920±0.069 Log10 and 
1.701±0.0707 Log10, respectively. 
 
 
A similar phenotype was observed by infecting IFN-γ deficient animals (Figure 14). In this case, animals 
infected with the ∆nrp-mutant had an average survival of 99 days, whereas those infected with the nrp-
complemented strain registered an average survival of 45 days (Figure 14A). Furthermore, animals 
infected with either strain had the same terminal bacterial burden, 8.357 vs 8.203 Log10 for ∆nrp-mutant 
and nrp-complemented infected animals, respectively (Figure 14B). Interestingly, animals infected with 
either strain displayed distinct immunopathological features at the time of death (Figure 14C and 14D). 
Notably, the differences in the histological phenotype observed in IFN-γ deficient animals infected with 
either strain resemble those observed in WT mice, where animals infected with the ∆nrp-mutant mutant 
develop smaller lesions than those infected with the nrp-complemented strain.  
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Figure 14: The ∆nrp-mutant presented reduced virulence in IFN-γ deficient mice. A) Survival curve of IFN-γ deficient 
mice infected with either the ∆nrp-mutant or the nrp-complemented strain, using 8 animals per curve. B) Bacterial burden of 
IFN-γ deficient animals at the time of death. H&E preparations of terminally ill IFN-γ deficient mice infected with C) the nrp-
complemented strain and D) ∆nrp-mutant magnified 40X. The presented images are representative of the entire group. Kaplan-
Meier curves analyzed using the log-rank (Mantel-Cox) test. ****p<0.0001. Initial bacterial burden for animals infected with the 
∆nrp-mutant and the nrp-complemented strain were 1.920±0.069 Log10 and 1.748±0.0707 Log10, respectively. 
 
Taken together, the data regarding the survival of animals with severely compromised or absent adaptive 
immunity show that nrp expression increased the virulence of Mtb, possibly by allowing the bacterium’s 
proliferation inside innate immune cells. Whether this is due to a circumvention of innate microbicidal 
mechanisms or an increased resistance to those mechanisms is the main question that arises from this 
part of the work and that we are currently investigating.  
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2.3.4. Innate immune deficiencies  
So far, we have showed that in the absence of nrp the innate immunity is better able to control Mtb. 
Specifically, the ∆nrp-mutant presents a slower growth in both mouse models of deficient adaptive 
immunity and during the innate phase of the immune response in WT mice when compared to the nrp-
complemented strain. In line with this, we proceeded to explore innate immune pathways that may account 
for the superior control over Mtb lacking nrp. For this purpose, we infected different mouse strains, 
available in our laboratory, deficient for the main surface TLRs involved in the recognition of Mtb, and in 
inflammatory mediators relevant in the early response this pathogen.  
 
2.3.4.1. Nrp-dependent virulence is not mediated by TLR-2 or TLR-4 activation 
To assess whether the improved control of the ∆nrp-mutant during the innate phase of the immune 
response (approximately the first 3 weeks post-infection) was dependent on signaling through TLR-2 or 
TLR-4, the main surface TLRs responsible for recognizing Mtb, we started by infecting mice deficient in 
either of these receptors. No significant differences regarding lung bacterial burdens were observed 
between these strains and WT mice (Figure 15A and 15B). Together, these data show that nrp is unlikely 
to modulate interactions between Mtb and the main surface TLRs responsible for recognizing this 
pathogen. 
 
Figure 15: nrp does not appear to modulate the recognition of Mtb by immune cells through TLR-2 and TLR-4. 
Lung bacterial burden over time in A) TLR-2 and B) TLR-4 deficient animals infected with the ∆nrp-mutant. Data analyzed 
performing a Two-way ANOVA using Sidak’s test for multiple comparisons. Each time-point contains data from 5 animals. Initial 
bacterial burden for animals infected with the ∆nrp-mutant was 1.920±0.069 Log10. 
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2.3.4.2. Nrp-dependent virulence is not mediated by the eicosanoid pathway 
 
Next we explored the eicosanoid pathway, as it has been reported that shifting arachidonic acid 
metabolism towards PGE2 production, in detriment of LTB4 and LXA4, results in a better control of 
infection 47,51. Accordingly, we infected ALOX 5 deficient mice which lack production of both LTB4 and LXA4, 
and ALOX 15 deficient mice, which lack LXA4 production, with the ∆nrp-mutant. We observed no 
significant differences regarding lung bacterial burden between these strains and WT mice (Figure 16A and 
16B). 
 
Figure 16: Shifting the eicosanoid pathway towards PGE2 production did not seem to impact control of the 
∆nrp-mutant. Lung bacterial burden over time in A) ALOX 5 and B) ALOX 15 deficient animals infected with the ∆nrp-mutant. 
Data analyzed performing a Two-way ANOVA using Sidak’s test for multiple comparisons. Each time-point contains data from 5 
animals. Each time-point contains data from 5 animals. Initial bacterial burden for animals infected with the ∆nrp-mutant was 
1.920±0.069 Log10. 
 
One possible scenario would be that the ∆nrp-mutant was selectively triggering PGE2 production, hence no 
phenotype would be observed by removing LTB4 or LXA4. To further investigate this hypothesis, ALOX 5 
and ALOX 15 deficient animals were infected with the nrp-complemented strain. This was not the case, as 
both ALOX 5 and ALOX 15 deficient animals displayed similar lung bacterial burdens as WT mice when 
infected with the nrp-complemented strain (Figure 17A and 17B). 
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Figure 17: The eicosanoid pathway was not modulated by nrp. Lung bacterial burden over time in A) ALOX 5 and B) 
ALOX 15 deficient animals infected with either the ∆nrp-mutant or the nrp-complemented strain. Data analyzed performing a 
Two-way ANOVA using Sidak’s test for multiple comparisons. Each time-point contains data from 5 animals. Initial bacterial 
burden for animals infected with the ∆nrp-mutant and the nrp-complemented strain were 1.920±0.069 Log10 and 1.701±0.071 
Log10, respectively. 
 
In summary, we showed that the phenotype observed in the absence of nrp is not due to a differential 
activation of innate immune cells via the main surface TLRs involved in Mtb recognition. Additionally, we 
have shown that the eicosanoid pathway is uninvolved with our phenotype.  
3. in vitro studies 
Considering all our data, it is clear that the phenotype observed with the ∆nrp-mutant occurs mainly during 
the innate phase of the immune response and is independent of TLR recognition and the eicosanoid 
pathway. To gain further insights on the mechanistic bases of this phenotype we next explored the in vitro 
infection of macrophages. We started by infecting BMDMs at a MOI of 1 in the presence or absence of IFN-
γ. BMDMs without IFN-γ activation should resemble macrophages during the innate phase of the immune 
response, whereas macrophages activated with this cytokine should resemble those found after the onset 
of the adaptive immune response. We found that BMDMs activated with IFN-γ appear to be equally capable 
controlling the ∆nrp-mutant and the nrp-complemented Mtb strains (Figure 18A, 18B and 18C). However, 
in the absence of IFN-γ the bacterial growth differed depending on the expression of nrp. Specifically, the 
number of viable nrp-complemented bacteria increased 0.2 Log10 between 4 and 96 hours post-infection 
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(Figure 18A and 18C), whereas no changes in the number of viable ∆nrp-mutant bacteria were observed 
between these time-points (Figure 18B and 18C). 
Similar results were obtained by infecting thioglycolate induced peritoneal macrophages (Figure 18D), a 
terminally differentiated type of macrophages. In this case, although both strains showed growth 96h post-
infection, this was on average 0.31 Log10 higher for the nrp-complemented strain. Unlike the results 
observed at 48h post-infection in BMDMs, peritoneal macrophages were better able to initially control the 
∆nrp-mutant. Specifically, the number of viable bacteria decreased at 48 hours post-infection for ∆nrp-
mutant and nrp-complemented strains, but this decrease was on average 0.22 Log10 for the ∆nrp-mutant 
(Figure 18D). 
 
Figure 18: nrp was required for optimal Mtb growth inside macrophages but did not protect against IFN-γ 
dependent mechanisms. Bacterial burden over time in BMDM infected with the A) ∆nrp-mutant or the B) nrp-complemented 
strain in the presence or absence of 100U/mL of IFN-γ. Variation of bacterial burden over time relative to 4 hours post-infection 
in C) BMDMs and D) thioglycolate induced peritoneal macrophages. Data analyzed performing a Two-way ANOVA using Sidak’s 
test for multiple comparisons. Each time-point contains pooled data from 2 separate experiments. ***p<0.001; *p<0.05 
A B 
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These in vitro data suggest that the differences observed in vivo may be largely due to the bacterium being 
less fit to proliferate within the phagocyte. One possibility is that nrp modulates the activation of the 
macrophage, making it a more permissive environment for the growth of the bacterium.  
To assess this hypothesis, we evaluated whether the production of RNS and inflammatory cytokines in 
BMDMs infected with Mtb expressing or not nrp. Our data showed that that as early as 48 hours after 
infection, BMDMs infected with the ∆nrp-mutant, but not those infected with the nrp-complemented strain, 
produce measureable levels of nitrites (Figure 19A and 19B). These differences are sustained until 96 
hours after infection (Figure 19B). In contrast, upon IFN-γ addition no differences were observed (Figure 
19C and 19D).  
 
Figure 19: The ∆nrp-mutant induced higher nitric oxide production than nrp-complemented Mtb. Nitrites 
concentration over time in the supernatants of BMDMs infected with either Mtb strain in the absence of IFN-γ at A) 48 and B) 
96 hours and in the presence of IFN-γ at C) 48 and D) 96 hours post-infection. Data analyzed performing unpaired t tests. Each 
time-point contains pooled data from 2 separate experiments. ***p<0.001 
A B 
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In all, these data may be suggestive that a differential recognition of the ∆nrp-mutant is in place, leading to 
a higher activation of the macrophage. This higher basal activation of the macrophage may in turn explain 
the previously observed differences in bacterial burdens. 
In addition to differences on nitric oxide production, we have also observed differential cytokine production 
by BMDM after 24 hours of infection. Specifically, we have assessed the concentration of TNF-α and IL-1β, 
two pro-inflammatory cytokines essential in the immune response to Mtb, and IL-10, a potent anti-
inflammatory cytokine (Figure 20). These data show that nrp modulates the activation of innate immune 
cells. Indeed, BMDMs infected with the ∆nrp-mutant produce higher amounts of TNF-α than those infected 
with the nrp-complemented strain (Figure 20A). Interestingly, the levels of IL-1β and IL-10 remain 
equivalent between infecting strains (Figure 20B and 20C), suggesting that the difference observed for 
TNF-α is specific and not due to possible intensity differences intrinsic to the ∆nrp-mutant. 
 
Figure 20: The ∆nrp-mutant induced higher production of TNF-α, but not IL-1β or IL-10, than the nrp-
complemented Mtb. Inflammatory cytokine concentration in the supernatants of BMDMs 24 hours after infection A) TNF-α B) 
IL-1β and C) IL-10. Data analyzed performing unpaired t tests. Results from two separate experiments. *p<0.05. 
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Despite decades of research, TB still remains a leading death cause by infectious disease, second only to 
the HIV pandemic3. Although clear progress has been made in tackling this disease, the fact that for 
decades little has changed in terms of anti-mycobacterial therapy4 and that no novel vaccine has proven 
more effective than BCG4 are proof that the current knowledge on TB pathophysiology is insufficient to 
achieve any major breakthrough in this field. The development of tools to genetically manipulate Mtb has 
allowed us to understand the role of specific pathogen molecules during infection, which may potentially 
reveal novel therapeutical targets96,123.  
In this work we have defined nrp has a novel Mtb virulence factor. This enzyme is required for optimal 
establishment of infection, as WT animals infected with the ∆nrp-mutant have a better control over 
infection at least until day 20 post-infection. This superior control subsides by day 30 post-infection, as the 
lung bacterial burden is similar for animals infected with either the ∆nrp-mutant or the nrp-complemented 
strain. Since our data show that the ∆nrp-mutant strain grows at similar rates as the nrp-complemented 
strain in both rich and minimal media, the reduced growth of the ∆nrp-mutant in vivo during the innate 
phase of infection is not associated with an intrinsic growth defect of this strain.   
Moreover, and as far as it is possible to assess with the low dose aerosol model, we have not observed any 
differences between strains regarding infectivity, as both display similar bacterial burdens after 3 days of 
infection. It would be important to closely monitor the immune response and bacterial burdens during the 
first weeks of infection, as this would allow us to determine whether the better control over the ∆nrp-
mutant is associated with an increased susceptibility of this deficient strain to the microbicidal mechanisms 
of macrophages or whether the specific innate immune response generated against this strain is more 
efficient at controlling bacterial growth. In this regard, we are currently assessing the bacterial burden and 
characterizing the innate response of animals infected with ∆nrp-mutant or the nrp-complemented strain at 
time points as early as day 7 and 14 post-infection.  
Although nrp expression increases the virulence of Mtb during the innate phase of the infection, allowing 
bacteria to grow more efficiently in infected macrophages, its expression did not allow evasion of the 
microbicidal mechanisms triggered by IFN-γ. Indeed, macrophages activated with IFN-γ are equally able to 
control Mtb regardless of nrp expression. Furthermore, these data go in line with the fact that upon the 
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arrival of an IFN-γ producing T cell response, both ∆nrp-mutant and nrp-complemented strains are 
controlled under a similar stable bacterial burden in WT animals.  
Although nrp is not required for the persistence of Mtb during the chronic phase of infection, in its absence 
mice develop a milder pathological response, as seen by the lower lesioned lung area in these animals in 
all timepoints assessed. These data suggest that the immune response of the initial phase of infection has 
important consequences for the immunopathological response generated during the chronic phase of 
infection. This is important because the pathology induced by Mtb is inflammatory in nature, and this 
response is responsible for the transmission of Mtb and ultimately to the death of the host5. In a clinical 
point of view, therapeutical interventions during the acute phase of infection may be more effective to 
prevent transmission of disease and development of pathological consequences to the host. 
Our cytometry data clearly showed different dynamics in the cellular immune response elicited by the 
∆nrp-mutant when compared to the nrp-complemented strain. Overall, we show that in the absence of nrp 
there is a delay in the recruitment of inflammatory monocytes and in their activation, as well as in the 
recruitment and activation of CD4+ T cells. An early influx of inflammatory monocytes may actually be 
detrimental to the host, as they typically lack MyD88 activation and overall microbicidal activity16,33. Indeed, 
it is well described that Mtb exploits CCR2 dependent recruitment of low-microbicidal monocytes33. This 
permissive phenotype of monocytes favors the development of a bacterium-friendly niche, as high 
accumulation of this cell type around infected macrophages blocks close contact between CD4+ T cells 
and bacterium-containing cells, thus impeding optimal activation of infected cells16.  
One hypothesis currently being assessed is whether the recruited monocytes have a different phenotype 
between infecting strains. Specifically, we are screening for the presence of NOS2 in recruited monocytes 
by flow cytometry. Our hypothesis is that, in the absence of nrp, alveolar macrophages will be differentially 
activated with higher triggering of MyD88, which in turn would lead to the recruitment of non-permissive 
monocytes (CD11b+Ly6ChiNOS2+)33. These monocytes are described to have higher microbicidal activity, 
thus allowing for better control of Mtb and potentially explaining the early bacterial load differences 
between infecting strains. One limitation with this approach is imposed by the difference in IFN-γ and the 
trend observed in CD4+ T cells by day 20 post-infection between strains. These differences could lead to 
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an increase in NOS2+ inflammatory monocytes in animals infected with the nrp-complemented strain. 
Therefore experiments are being carried out in both WT and RAG-2 deficient mice.  
Another piece of data that fits in this hypothesis is the delayed appearance and stabilization at lower 
bacterial burden, of the ∆nrp-mutant, in the spleen of infected animals. Specifically, it has been shown that 
bacterial dissemination is facilitated by myeloid cells recruited in a CCR2/CCL2 dependent manner, as 
these cells are able to move in and out of the local of infection, therefore carrying the bacterium to 
secondary targets of infection16. Our gene expression data showed the lower expression levels of Ccl2 for 
day 20 post-infection in the lungs of ∆nrp-mutant infected mice. This lower expression may indeed account 
for the delayed dissemination of the bacterium to the spleen. On the other hand, when dissemination does 
indeed happen, there is already a robust Mtb-specific T cell response capable of controlling the bacterium’s 
growth16. It equally possible that the phenotype observed in the spleen is the result of an impaired ability of 
the ∆nrp-mutant to grow in the specific environment of the spleen. In this case, an intravenous infection 
should shed light on this issue, as the spleen would be a primary organ of infection, and not a target of 
dissemination. 
A possible confounding factor regarding the flow cytometry data is the marked difference in bacterial 
burden at day 20 post-infection. One possible hypothesis is that the ∆nrp-mutant does indeed induce a 
differential innate immune response which accounts for the differences in cell recruitment and the lower 
bacterial burden itself. Another equally valid hypothesis is that the lower numbers of inflammatory 
monocytes and activated CD4+ T cells are the result of a burden-dependent response. In the future, a high 
dose aerosol infection will be carried out to account for this variable. In this case, it is expected that by day 
20 post-infection the ∆nrp-mutant infected animals would have an equivalent bacterial load when 
compared to the low dose aerosol nrp-complemented infected mice. In this case, assuming that nrp does 
indeed induce a differential immune response, we should still obtain a discernible phenotype regarding cell 
recruitment and activation dynamics. 
A striking feature that our data has revealed are the differences regarding immunopathology in the lungs of 
animals infected with either Mtb strain. Even though differences in tissue pathology at day 20 post-infection 
can easily be attributed to the differential bacterial load, this does not justify the long term differences 
observed. Indeed, nrp is essential to the development of extensive immunopathology, as seen by the higher 
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percentage of lesioned area in the lungs of animals infected with the nrp-complemented. These differences 
are even observed in extreme settings, as is the case of moribund IFN-γ deficient animals. Furthermore, in 
the absence of nrp there is an apparent increased number of individual lesions, although with smaller area. 
This feature will be quantified in the future, as it may yield important information on the initial events that 
drive granulomatous lesion formation in the presence or absence of nrp. How these features would 
translate into Mtb transmission would be an interesting question, as it is hypothesized that some degree of 
immunopathology must be achieved in order for the bacterium to be expelled from the infected lung9. 
Taking this into consideration, it will be important to assess both host and pathogen molecular players 
responsible for granuloma formation. One question raised by these structural differences is whether the 
bacterial TDM, the main inducer of granuloma formation, is in any way altered in the absence of nrp.  
One key host factor that would fit with both differences in immunopathology and permissive monocyte 
recruitment would be the induction of matrix metalloproteinases (MMPs)124–126. On one hand, MMP9 is 
described to be induced upon Mtb’s Esx-A delivery to epithelial cells, in turn inducing the recruitment of 
permissive monocytes through an unknown mechanism, leading to the formation of large lesions and 
eventually a granuloma-like structure125. On the other hand, MMP1 has been reported to breakdown the 
collagen matrix responsible for granting granulomas structural integrity124. If nrp induces the expression of 
MMP1, the otherwise smaller lesions would be disrupted, allowing Mtb to spread into adjacent tissue, 
leading to wider lesions. Taking this into consideration, the expression levels of these enzymes will be 
measured in the future. Another factor that could partially account for the histopathological differences is 
the type of adaptive response triggered. We are currently phenotyping the adaptive immune response on 
day 45 post-infection, as by this time the initial differences observed in bacterial burdens should have little 
impact. One possible scenario would be that in the absence of nrp, the effector T cell response displays 
less Th17 cell differentiation, which is known to contribute for excessive inflammation. In either case, the 
fact that IFN-γ deficient animals still present immunopathological differences makes it highly unlikely for a 
differential Th response to be a defining factor in this phenotype.  
Taking into consideration our data, it is evident that nrp exerts its virulence during the innate phase of the 
immune response, both considering the timeframe in which bacterial burden differences are observed and 
the survival of animals with severely compromised or absent adaptive immune responses. It is possible 
that the differential phenotype observed between innate and acquired immune responses may result from 
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a differential expression of nrp throughout infection. Indeed, the bacterium itself may regulate the 
expression of nrp throughout time, since nrp is the most abundant Mtb protein in the lungs of guinea pigs 
infected with H37Rv by day 30, whereas it is under detection levels by day 9034. Why and whether Mtb 
does this is a matter of speculation. On one hand, if nrp is no longer required during the chronic phase of 
infection it would be a poor energetic strategy to waste metabolic resources into an unrequired 2512 
amino acid long protein. On the other hand, Mtb may do so to slow disease progression in order to prolong 
its host’s life and increase chances of transmission. In either case, following the transcriptional kinetics of 
Nrp should yield valuable information on which phases of infection this virulence factor is needed. In this 
line, we are planning to measure the expression of nrp from the bacteria extracted from the lungs of 
infected animals at different time-points post-infection. 
The hypothesis that nrp plays a role in the recognition of Mtb by innate immune cells, goes in line with our 
data. We have seen differences regarding TNF-α and nitrites production in in vitro models of macrophage 
infection. One possible scenario would be that in the absence of nrp Mtb would be more easily recognized 
by TLR-4, which in turn would lead to RNS production and enhanced TNF-α production in a TIR-domain-
containing adapter-inducing interferon-β (TRIF) dependent fashion88. However, since there are no 
discernible differences between WT and TLR-4 deficient animals infected with the ∆nrp-mutant this 
hypothesis is unlikely. It is also unlikely that these differences are due to a differential inflammasome 
activation, as these should lead to differential production of IL-1β44, which is not the case. As nrp does not 
appear to decisively mediate interactions with either TLR-2 or TLR-4, in the future it may be worth to assess 
if it impacts Mtb recognition by other PRRs (e.g. NOD receptors and CLRs).   
Considering the phenotype concerning CFUs during in vitro infections, they may indeed reflect what is 
happening inside the phagocyte during in vivo infections, as we have observed a consistent result regarding 
variation in bacterial burden between 4 and 96 hours post-infection in two different types of macrophages. 
It would be interesting to prolong these experiments beyond 96 hours, as longer time-points may yield 
more pronounced differences between the ∆nrp-mutant and the nrp-complemented strain. However, our 
experimental setup does not allow for longer time-points, as this would result in macrophage death, thus 
limiting the accurate determination of intracellular bacterial burden. Alternatively, a phagocytic cell line may 
be used in the future to overcome this limitation127.  
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One particular issue that must be considered in these in vitro infections is whether Nrp is being expressed 
at the time of infection, and if not, how long it takes until it is. It is not uncommon for virulence factors that 
are only required during infection to be downregulated under culture conditions128, such as those 
encountered in the inoculum used for these infections. The fact that the absence of nrp leads to a 
phenotype in macrophage infection, is a good indicator that the nrp-complemented strain is indeed 
expressing this molecule. However, if nrp expression is delayed, the differences observed by infecting 
macrophages with either the ∆nrp-mutant or the nrp-complemented strain may not fully represent the 
impact of nrp. Taking this into consideration, in the future it will also be important to assess Nrp expression 
in culture conditions and at different time-points shortly after in vitro infection of macrophages.  
Taking into consideration the consistent induction of RNS production and our hypothesis of non-permissive 
NOS2+ monocyte recruitment in the absence of nrp, an experiment with mice infected with the ∆nrp-
mutant while treated with aminoguanidine35, a NOS2 inhibitor, is currently being performed. A similar 
rational will be performed in an in vitro setting to determine whether nitric oxide is responsible for the 
growth deficit of the ∆nrp-mutant. RNS production is only one among many possible microbicidal 
mechanisms that may be behind the phenotype in the absence of nrp. Another mechanism worth exploring 
in vitro that could explain the lower bacterial burden in the absence of nrp, both in in vivo and in vitro 
settings, is phagosomal acidification, which can be performed using LysoTracker36. 
One obvious disadvantage on studying a previously uncharacterized enzyme is that there is no knowledge 
on what it is actually synthesizing, and therefore inferring on the possible differential interactions between 
host and pathogen is largely an empirical try and error approach. As such, in the future a detailed 
bioinformatics analysis on this gene and of the remainder of its operon will be performed. Additionally, a 
characterization of the differences in cell wall lipids between the ∆nrp-mutant and the nrp-complemented 
strain following different experimental conditions (e.g. infection, culture) will also be carried out. 
Lastly, a thorough characterization of the ∆nrp-mutant and nrp-complemented strains growth and 
resistance under stress conditions will also be performed. These experiments may indicate whether there is 
a specific stress factor under which nrp is required for Mtb’s resistance or whether its cell wall integrity is 
compromised. These conditions will include nitrosative and oxidative stress, extreme pH, nutrient 
deprivation, divalent cation deprivation (Fe2+, Mg2+) and detergent exposure129–134. With the exception of 
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detergent exposure, these conditions were chosen since they are known to be scenarios encountered by 
Mtb inside the macrophage129. Therefore, failure for the ∆nrp-mutant, but not the nrp-complemented strain, 
to grow in any of these conditions could be a good indicator of the growth-limiting stress factor encountered 
by the ∆nrp-mutant inside the host. Additionally, the detergent exposure experiment will allow us to 
evaluate whether the absence of nrp leads to a loss of cell wall structural integrity. 
To the furthest of our knowledge, the survival phenotype observed in IFN-γ and RAG-2 deficient animals in 
the absence of nrp is the strongest reported to date. All our data point towards nrp as a virulence factor 
predominantly during the innate phase of the immune response. Considering our data, nrp inhibition may 
prove as a suitable drug target against TB, especially in cases of HIV co-infection.  
Several parallels may be drawn from infection models of severe adaptive immune deficiency, such as the 
IFN-γ and RAG-2 deficient animals, with TB-HIV patients. Both have a predominately and prolonged non-
protective innate immune response to Mtb, rapidly developing an often lethal severe and disseminated 
form of TB3–5. HIV positive cases still account for more than 25% of deaths due to TB. It is our reasoning 
that nrp inhibition may slow down disease progression, allowing for a better timeframe to treat these high 
risk patients. 
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Figure 21: Summary of the main findings and questions resulting of this thesis. Briefly, alveolar 
macrophages/inflammatory monocytes are differentially activated in the absence of nrp, producing more nitric oxide and TNF. 
The ∆nrp-mutant is better controlled during the innate phase of the immune response, either due to a loss of fitness or due to 
an increased microbicidal activity of phagocytes. In the absence of nrp, there is a delayed dissemination to peripheral organs 
and a decreased influx of inflammatory monocytes to the lung, hypothetically in part due to a decreased CCL2 production. This 
results in a delayed mounting of an adaptive immune response, and consequently a lower influx of lymphocytes to the site of 
infection. This decreased influx of lymphocytes and inflammatory monocytes is likely to contribute to the smaller size of the lung 
lesions observed in animals infected with the ∆nrp-mutant. Additionally, the delayed detection of Mtb in the spleen and its 
control under a lower bacterial burden suggests that there is already a protective Mtb-specific T cell response shortly after 
dissemination to this organ.  
 
In this work we have described nrp as a virulence factor of Mtb, exerting its function mainly during the 
innate phase of the immune response with important long term pathophysiological consequences. Whether 
nrp exerts its role by conferring Mtb resistance to microbicidal mechanisms or by differentially activating 
phagocytes, will be the subject of our future work. We expect that using this type of approach, studying 
simultaneously host and pathogen factors will benefit greatly our current knowledge of the events taking 
place in TB. 
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